AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37903324 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspacytarabine 4.5 g/m2 per day for 6 doses
Number of subjects: 65
Study 37903324 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspacytarabine in patients with secondary AML
Number of subjects: 65
Study 37903324 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspacytarabine in patients with prior treatment with hypomethylating agents
Number of subjects: 65
Study 37903324 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspacytarabine in patients with TP53 mutation
Number of subjects: 65
Study 37903324 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspacytarabine overall
Number of subjects: 65
Study 37903324 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspacytarabine
Number of subjects: 65
Study 37903325 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab before JCAR014 infusion
Number of subjects: 100
Study 37903325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing durvalumab therapy after JCAR014
Number of subjects: 100
Study 37903325 — intervention group
Group type: COMPARATOR
Intervention: JCAR014 alone (control)
Number of subjects: 100
Study 37903365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively enhanced tai ji quan
Number of subjects: 318
Study 37903367 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored implementation of unit-based physician teams, unit nurse-physician coleadership, enhanced interprofessional rounds, unit-level performance reports, and patient engagement activities
Number of subjects: 155
Study 37903367 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 155
Study 37903440 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics administered (2,296 antibiotic regimens; 95.7% intravenous, 4.3% oral)
Number of subjects: 1867
Study 37903440 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed and administered on admission day
Number of subjects: 1867
Study 37903440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing accuracy of intravenous ciprofloxacin regimens
Number of subjects: 1867
Study 37903440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous-to-oral switch
Number of subjects: 1867
Study 37903440 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-dose tablets splitting
Number of subjects: 1867
Study 37903465 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous LH administration during ovarian stimulation
Number of subjects: 43
Study 37903465 — intervention group
Group type: COMPARATOR
Intervention: Low LH levels during ovarian stimulation
Number of subjects: 43
Study 37903483 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 690517 (3 mg, 10 mg, or 20 mg)
Number of subjects: 714
Study 37903483 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 714
Study 37903483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714
Study 37903504 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab plus chemotherapy
Number of subjects: 0
Study 37903504 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual viable tumor (RVT) in primary tumor (PT)
Number of subjects: 0
Study 37903504 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic response assessment
Number of subjects: 0
Study 37903504 — intervention group
Group type: EXPERIMENTAL
Intervention: %RVT
Number of subjects: 0
Study 37903568 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 76
Study 37903568 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 76
Study 37903568 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab or Azathioprine (not specified which for this outcome)
Number of subjects: 76
Study 37903590 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (adjuvant treatment)
Number of subjects: 0
Study 37903590 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 37903607 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month SMS texting strategy
Number of subjects: 120
Study 37903607 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 120
Study 37903608 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (headset with virtual reality session)
Number of subjects: 0
Study 37903608 — intervention group
Group type: COMPARATOR
Intervention: Control (headset with no image nor audio)
Number of subjects: 0
Study 37903679 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA BNT162b2
Number of subjects: 458
Study 37903679 — intervention group
Group type: COMPARATOR
Intervention: AdV AZD1222
Number of subjects: 458
Study 37903818 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free dexamethasone 0.1% eye drops
Number of subjects: 40
Study 37903818 — intervention group
Group type: COMPARATOR
Intervention: Preserved dexamethasone 0.1% eye drops
Number of subjects: 40
Study 37903856 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port robotic distal gastrectomy (SPRDG) using the da Vinci SP system
Number of subjects: 19
Study 37903861 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day
Number of subjects: 90
Study 37903861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 37903899 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (median of 20 cycles)
Number of subjects: 15
Study 37903899 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 15
Study 37903909 — intervention group
Group type: EXPERIMENTAL
Intervention: GV1001 plus gemcitabine/capecitabine
Number of subjects: 148
Study 37903909 — intervention group
Group type: COMPARATOR
Intervention: Control (gemcitabine/capecitabine alone)
Number of subjects: 148
Study 37903951 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging-guided localization (IGL)
Number of subjects: 500
Study 37903951 — intervention group
Group type: COMPARATOR
Intervention: No IGL (Control)
Number of subjects: 500
Study 37903951 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IGL and No IGL
Number of subjects: 500
Study 37904082 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% loading dose for six months followed by 0.01% for six months (N=33)
Number of subjects: 97
Study 37904082 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% for twelve months (N=32)
Number of subjects: 97
Study 37904082 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle for twelve months, N=32)
Number of subjects: 97
Study 37904091 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT (N=50)
Number of subjects: 150
Study 37904091 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS (N=50)
Number of subjects: 150
Study 37904091 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N=50)
Number of subjects: 150
Study 37904091 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT and TMS
Number of subjects: 150
Study 37904229 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs) embedded in Tissucol Duo
Number of subjects: 6
Study 37904241 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2.5 mg IV every 8 hours, titrated up to 5 mg if delirium persisted until ICU discharge or up to 14 days
Number of subjects: 132
Study 37904241 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 132
Study 37904241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 37904247 — intervention group
Group type: EXPERIMENTAL
Intervention: TH-SC01 cells (120 million cells, single intralesional injection)
Number of subjects: 10
Study 37904250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (2 mg/day for 5-7 days)
Number of subjects: 0
Study 37904314 — intervention group
Group type: EXPERIMENTAL
Intervention: Seladelpar 5 or 10 mg orally once daily
Number of subjects: 106
Study 37904861 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain medication intake
Number of subjects: 189
Study 37904861 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Active Motion (TAM)
Number of subjects: 189
Study 37904861 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH scores
Number of subjects: 189
Study 37904861 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 189
Study 37904861 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain levels
Number of subjects: 189
Study 37905193 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotoner™ compression gloves
Number of subjects: 73
Study 37905356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet fasted (100 mg peposertib)
Number of subjects: 12
Study 37905356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet fed (100 mg peposertib)
Number of subjects: 12
Study 37905356 — intervention group
Group type: EXPERIMENTAL
Intervention: OS fasted (100 mg peposertib)
Number of subjects: 12
Study 37905421 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week patch monitors for AF screening
Number of subjects: 0
Study 37905421 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 37905540 — intervention group
Group type: EXPERIMENTAL
Intervention: B-SWELL intervention
Number of subjects: 48
Study 37905540 — intervention group
Group type: COMPARATOR
Intervention: Wellness intervention
Number of subjects: 48
Study 37905548 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/1h hs-cTnI point of care (POC) instrument
Number of subjects: 1500
Study 37905548 — intervention group
Group type: COMPARATOR
Intervention: Central laboratory hs-cTnT measurements
Number of subjects: 1500
Study 37905704 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) with xenografts
Number of subjects: 36
Study 37905704 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable platelet-rich fibrin (I-PRF) with xenografts
Number of subjects: 36
Study 37905704 — intervention group
Group type: COMPARATOR
Intervention: Xenografts alone (Control)
Number of subjects: 36
Study 37905734 — intervention group
Group type: EXPERIMENTAL
Intervention: Varnimcabtagene autoleucel (var-cel)
Number of subjects: 45
Study 37905906 — intervention group
Group type: EXPERIMENTAL
Intervention: Expander with differential opening (EDO)
Number of subjects: 48
Study 37905906 — intervention group
Group type: COMPARATOR
Intervention: Fan-type expander (FE)
Number of subjects: 48
Study 37905906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both expanders (EDO and FE)
Number of subjects: 48
Study 37906009 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 1177
Study 37906009 — intervention group
Group type: COMPARATOR
Intervention: Immediate Surgery
Number of subjects: 1177
Study 37906216 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor (CGM; Medtronic Guardian)
Number of subjects: 10
Study 37906216 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity sensors (activity bracelet - Garmin Vivosmart 3, hip-worn sensor - UKK Exsed, electrocardiography sensor - Firstbeat 2)
Number of subjects: 10
Study 37906216 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Theory of Acceptance and Use of Technology (UTAUT) questionnaire
Number of subjects: 10
Study 37906216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app combining glucose, nutrition, and physical activity data
Number of subjects: 10
Study 37906406 — intervention group
Group type: EXPERIMENTAL
Intervention: Less neurotoxic regimen consisting of darunavir/cobicistat plus emtricitabine plus maraviroc
Number of subjects: 0
Study 37906406 — intervention group
Group type: COMPARATOR
Intervention: Maintaining actual care (control group)
Number of subjects: 0
Study 37906417 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (100 mg subcutaneous injections at Week 0, Week 4, then every 8 weeks in psoriasis; every 4 weeks or every 8 weeks in PsA)
Number of subjects: 4399
Study 37906417 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 4399
Study 37906649 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib + Trastuzumab + Fulvestrant (Arm A)
Number of subjects: 237
Study 37906649 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib + Trastuzumab (Arm B)
Number of subjects: 237
Study 37906649 — intervention group
Group type: COMPARATOR
Intervention: SOC Chemotherapy + Trastuzumab (Arm C)
Number of subjects: 237
Study 37906649 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminal subtypes (exploratory analysis)
Number of subjects: 237
Study 37906724 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS + HIPEC (CRS + H)
Number of subjects: 105
Study 37906724 — intervention group
Group type: COMPARATOR
Intervention: CRS alone (CRS-A)
Number of subjects: 105
Study 37906726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofranergene obadenovec (ofra-vec) with weekly paclitaxel
Number of subjects: 409
Study 37906726 — intervention group
Group type: COMPARATOR
Intervention: Placebo with weekly paclitaxel
Number of subjects: 409
Study 37907210 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrotinib (400 mg once daily) combined with trastuzumab (8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2)
Number of subjects: 590
Study 37907210 — intervention group
Group type: COMPARATOR
Intervention: placebo combined with trastuzumab (8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2)
Number of subjects: 590
Study 37907210 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrotinib (400 mg once daily)
Number of subjects: 590
Study 37907210 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 590
Study 37907210 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrotinib, trastuzumab, and docetaxel
Number of subjects: 590
Study 37907210 — intervention group
Group type: COMPARATOR
Intervention: placebo, trastuzumab, and docetaxel
Number of subjects: 590
Study 37907221 — intervention group
Group type: EXPERIMENTAL
Intervention: NIZ985 (1 µg/kg TIW)
Number of subjects: 83
Study 37907221 — intervention group
Group type: EXPERIMENTAL
Intervention: NIZ985 (1 µg/kg TIW) + spartalizumab (400 mg Q4W)
Number of subjects: 83
Study 37907221 — intervention group
Group type: EXPERIMENTAL
Intervention: NIZ985 (single-agent)
Number of subjects: 83
Study 37907221 — intervention group
Group type: EXPERIMENTAL
Intervention: NIZ985 + spartalizumab
Number of subjects: 83
Study 37907305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin lead-in followed by rivaroxaban
Number of subjects: 60
Study 37907305 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban alone
Number of subjects: 60
Study 37907448 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational heat stress recommendation compliance
Number of subjects: 0
Study 37907448 — intervention group
Group type: COMPARATOR
Intervention: Work-rest ratio-matched positive control scenario
Number of subjects: 0
Study 37907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 1348
Study 37907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (i.v. thrombolysis)
Number of subjects: 1348
Study 37907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1348
Study 37907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-stroke modified Rankin scale (mRS)
Number of subjects: 1348
Study 37907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NIHSS
Number of subjects: 1348
Study 37907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1348
Study 37907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of passes during thrombectomy
Number of subjects: 1348
Study 37907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage
Number of subjects: 1348
Study 37907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissections, perforations
Number of subjects: 1348
Study 37907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Clot migration, embolization
Number of subjects: 1348
Study 37907503 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of Immunity-and-matrix-regulatory cells (IMRCs)
Number of subjects: 18
Study 37907503 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection of umbilical cord MSCs (as a comparison)
Number of subjects: 18
Study 37907796 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg L-citrulline every 6 hours for 72 hours
Number of subjects: 6
Study 37907858 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel mobility intervention (information and exercise booklets, mobility diary, iPad with exercise videos, e-learning for healthcare professionals, oral presentation, mobility checklist, posters and pictures on the wards)
Number of subjects: 274
Study 37907858 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel mobility intervention
Number of subjects: 274
Study 37907858 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 274
Study 37907927 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle tenotomy
Number of subjects: 244
Study 37907927 — intervention group
Group type: COMPARATOR
Intervention: Blade tenotomy
Number of subjects: 244
Study 37907990 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based pelvic floor muscle training (PFMT) delivered by a midwife
Number of subjects: 48
Study 37907990 — intervention group
Group type: COMPARATOR
Intervention: Usual antenatal care (control group)
Number of subjects: 48
Study 37908003 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies for patients with SMI
Number of subjects: 20
Study 37908003 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of GP interviews
Number of subjects: 20
Study 37908003 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative analysis of recruitment process
Number of subjects: 20
Study 37908009 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal birth after cesarean
Number of subjects: 8267
Study 37908009 — intervention group
Group type: COMPARATOR
Intervention: Repeat cesarean birth
Number of subjects: 8267
Study 37908016 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 19
Study 37908016 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 19
Study 37908016 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 19
Study 37908359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DTG/3TC)
Number of subjects: 66
Study 37908359 — intervention group
Group type: COMPARATOR
Intervention: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
Number of subjects: 66
Study 37908441 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-learning methodology for CCTA analysis from co-registered NIRS-IVUS and CCTA data
Number of subjects: 70
Study 37908441 — intervention group
Group type: COMPARATOR
Intervention: Conventional CCTA expert analysis
Number of subjects: 70
Study 37908549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermuscular adipose tissue (IMAT) measurements
Number of subjects: 1781
Study 37908549 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimuscular adipose tissue (PAT) measurements
Number of subjects: 1781
Study 37908552 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA-derived fractional flow reserve (FFR)
Number of subjects: 4290
Study 37908552 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA and CT-FFR findings
Number of subjects: 4290
Study 37908625 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP web-based intervention
Number of subjects: 97
Study 37908625 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 37908625 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP web-based intervention (women)
Number of subjects: 97
Study 37909020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, FLOT, and trastuzumab
Number of subjects: 30
Study 37909386 — intervention group
Group type: COMPARATOR
Intervention: tofacitinib (placebo-controlled trials)
Number of subjects: 330
Study 37909532 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Number of subjects: 126
Study 37909532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-assisted education
Number of subjects: 126
Study 37909532 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 126
Study 37909624 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycystic ovary syndrome group (n=37)
Number of subjects: 57
Study 37909624 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 57
Study 37910105 — intervention group
Group type: EXPERIMENTAL
Intervention: SAAF intervention (7-session, 14 hours over 7 weeks)
Number of subjects: 472
Study 37910105 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 472
Study 37910157 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal2Quit mobile app intervention with a 2-week sample of combination nicotine replacement therapy (NRT)
Number of subjects: 150
Study 37910157 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (self-help booklet for quitting smoking not tailored for depression)
Number of subjects: 150
Study 37910166 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (100 mg/kg body weight daily) with exercise (high-volume, moderate-intensity, whole-body exercise training 3 times per week for 8 weeks)
Number of subjects: 30
Study 37910166 — intervention group
Group type: COMPARATOR
Intervention: Exercise (high-volume, moderate-intensity, whole-body exercise training 3 times per week for 8 weeks)
Number of subjects: 30
Study 37910313 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor (5 to 30 mg/dose, orally, twice-daily for 16 weeks)
Number of subjects: 54
Study 37910335 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0
Study 37910523 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded Enoxaparin (BE)
Number of subjects: 168
Study 37910523 — intervention group
Group type: COMPARATOR
Intervention: Biosimilar Enoxaparin (BSE)
Number of subjects: 168
Study 37910603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 11
Study 37910603 — intervention group
Group type: COMPARATOR
Intervention: Observation period followed by delayed FMT if stool cultures were MDRO positive at day 36
Number of subjects: 11